KCPG
TXMD icon

Kavar Capital Partners Group’s TherapeuticsMD TXMD Stock Holding History

Kavar Capital Partners Group’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-50
Closed -$16K – 352
2018
Q2 		$16K Hold
50
– – 0.01% 282
2018
Q1 		$12K Buy
+50
New +$14K 0.01% 306

Other funds holding TXMD

Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
DCM
Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $96.1B AUM 40.06% 1-Year Est. Return

Kavar Capital Partners Group's TXMD Position: Q3 2018 in Review

Kavar Capital Partners Group sold out of TherapeuticsMD (TXMD) in Q3 2018, closing a stake of 50 shares — an estimated $16K sold.

Kavar Capital Partners Group first reported a position in TXMD in Q1 2018 and held it in 2 quarters. The position peaked at $16K in Q2 2018. 155 funds tracked by Wall St. Rank hold TXMD as of Q3 2018.

  • Kavar Capital Partners Group reported no remaining TherapeuticsMD position as of Q3 2018 after selling out during the quarter.
  • Kavar Capital Partners Group sold 50 TherapeuticsMD shares in Q3 2018, an estimated $16K.
  • Kavar Capital Partners Group first reported a position in TherapeuticsMD in Q1 2018 and held it in 2 quarters.
  • Kavar Capital Partners Group's TherapeuticsMD position peaked at $16K in Q2 2018.
  • 155 funds tracked by Wall St. Rank held TherapeuticsMD as of Q3 2018.

Based on Kavar Capital Partners Group's 13F filing for Q3 2018, filed 9 Nov 2018.